Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats

References

• Ward N, Milstien J, Hull H, Hull B. A global overview and hope for the eradication of poliomyelitis by the year 2000. Trop Geogr Med 1993; 45(5):198-202; PMID:8279055.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004. MMWR Morb Mortal Wkly Rep 2004; 53(42):990-3; PMID:15514582
   PubMedGoogle Scholar
• Norris A, Hachey K, Curtis A, Bourdeaux M. Crippling violence: Conflict and incident polio in Afghanistan. PLoS One 2016; 11:e0149074; PMID:26958854; http://dx.doi.org/10.1371/journal.pone.0149074
   PubMed Web of Science ®Google Scholar
• Khan MU, Ahmad A, Aqeel T, Akbar N, Salman S, Idress J. A cross-sectional survey of healthcare workers on the knowledge and attitudes towards polio vaccination in Pakistan. PLoS One 2015; 10:e0142485; PMID:26559184; http://dx.doi.org/10.1371/journal.pone.0142485
   PubMed Web of Science ®Google Scholar
• Manya S, Qazi J. From Pakistan a line of hope for ‘The polio eradication and endgame strategic plan 2013–2018’. Infect Dis (Lond) 2016; 48:167-8; PMID:26417889; http://dx.doi.org/10.3109/23744235.2015.1092050
   PubMed Web of Science ®Google Scholar
• Wang HB, Zhu SL, Zheng JS, Gou AL, Cui H, Zhang Y, Ning GJ, Fan CX, Chen YS, Li KL, et al. Sero-survey of polio antibodies during wild poliovirus outbreak in southern Xinjiang Uygur Autonomous Region, China. PLoS One 2014; 9:e80069; PMID:24991811; http://dx.doi.org/10.1371/journal.pone.0080069
   PubMedGoogle Scholar
• Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587-635; PMID:16153180; http://dx.doi.org/10.1146/annurev.micro.58.030603.123625
   PubMed Web of Science ®Google Scholar
• Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, Garnier S, Chauvin C, Abanida E, Pate MA, Adu F, Baba M, Grassly NC. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 2010; 362:2360-9; PMID:20573924; http://dx.doi.org/10.1056/NEJMoa0910074
   PubMed Web of Science ®Google Scholar
• Sutter RW, Caceres VM, Mas Lago P. The role of routine polio immunization in the post-certification era. Bull World Health Organ 2004; 82:31-9; PMID:15106298
   PubMed Web of Science ®Google Scholar
• Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 2006; 81:137-44; PMID:16673508
   PubMedGoogle Scholar
• Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis 2014; 210(Suppl 1):S459-64; PMID:25316868; http://dx.doi.org/10.1093/infdis/jiu128
   PubMedGoogle Scholar
• Muller DA, Pearson FE, Fernando GJ, Agyei-Yeboah C, Owens NS, Corrie SR, Crichton ML, Wei JC, Weldon WC, Oberste MS, et al. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Sci Rep 2016; 6:22094; PMID:26911254; http://dx.doi.org/10.1038/srep22094
   PubMed Web of Science ®Google Scholar
• Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 27–28 November 2007. Wkly Epidemiol Rec 2008; 83:25-35; PMID:18203406
   PubMedGoogle Scholar
• Bruce Aylward R, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Risk management in a polio-free world. Risk Anal 2006; 26:1441-8; PMID:17184391; http://dx.doi.org/10.1111/j.1539-6924.2006.00840.x
   PubMed Web of Science ®Google Scholar
• Polio Eradication Initiative. Cessation of routine oral polio vaccine (OPV) use after global polio eradication: Framework for national policy makers in OPV-using countries. Geneva, Switzerland: World Health Organization 2005.
   Google Scholar
• Dietrich J, Andreasen LV, Andersen P, Agger EM. Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. PLoS One 2014; 9:e100879; PMID:24956110; http://dx.doi.org/10.1371/journal.pone.0100879
   PubMed Web of Science ®Google Scholar
• Thomassen YE, van 't Oever AG, van Oijen MG, Wijffels RH, van der Pol LA, Bakker WA. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS One 2013; 8:e83374; PMID:24349497; http://dx.doi.org/10.1371/journal.pone.0083374
   PubMed Web of Science ®Google Scholar
• Mahmood K, Pelkowski S, Atherly D, Sitrin RD, Donnelly JJ. Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries. Hum Vaccin Immunother 2013; 9:1894-902; PMID: 23787559; http://dx.doi.org/10.4161/hv.25407
   Google Scholar
• van der Maaden K, Trietsch SJ, Kraan H, Varypataki EM, Romeijn S, Zwier R, van der Linden HJ, Kersten G, Hankemeier T, Jiskoot W, et al. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats. Pharm Res 2014; 31:1846-54; PMID:24469907
   PubMed Web of Science ®Google Scholar
• McAllister L, Anderson J, Werth K, Cho I, Copeland K, Le Cam Bouveret N, Plant D, Mendelman PM, Cobb DK. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet 2014; 384:674-81; PMID:24881803; http://dx.doi.org/10.1016/S0140-6736(14)60524-9
   PubMed Web of Science ®Google Scholar
• Lebre F, Borchard G, de Lima MC, Borges O. Progress towards a needle-free hepatitis B vaccine. Pharm Res 2011; 28:986-1012; PMID:21088986; http://dx.doi.org/10.1007/s11095-010-0314-4
   PubMed Web of Science ®Google Scholar
• Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen N, Caux C, Aït-Yahia S, Vicari A, Kaiserlian D, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 2006; 24:191-201; PMID:16473831; http://dx.doi.org/10.1016/j.immuni.2006.01.005
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis 2012; 205:237-43; PMID:22158682; http://dx.doi.org/10.1093/infdis/jir723
   PubMed Web of Science ®Google Scholar
• Kouiavskaia D, Mirochnitchenko O, Dragunsky E, Kochba E, Levin Y, Troy S, Chumakov K. Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study. J Infect Dis 2014; PMID:25391313
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Mach O, Fonseca M, Diaz M, Alemany N, Garcia G, Hung LH, Martinez Y, Sutter R. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine 2015; 33:307-13; PMID:25448109; http://dx.doi.org/10.1016/j.vaccine.2014.11.025
   PubMed Web of Science ®Google Scholar
• Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MM, Sharif SM, van der Avoort HG, Pallansch MA, Malankar P, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010; 362:2351-9; PMID:20573923; http://dx.doi.org/10.1056/NEJMoa0909383
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, Alemani N, Galindo B, Burton A, Friede M, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010; 201:1344-52; PMID:20350164; http://dx.doi.org/10.1086/651611
   PubMed Web of Science ®Google Scholar
• Soonawala D, Verdijk P, Wijmenga-Monsuur AJ, Boog CJ, Koedam P, Visser LG, Rots NY. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine 2013; 31:3688-94; PMID:23770332; http://dx.doi.org/10.1016/j.vaccine.2013.05.104
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Vidor E. Poliovirus vaccine–inactivated. In: Plotkin SA, Orenstein WA (eds) Vaccines, 4th edition. Philadelphia, PA: Saunders. 2004; 24:625-49.
   Google Scholar
• Resik S, Tejeda A, Sutter RW, Diaz M, Sarmiento L, Alemani N, Garcia G, Fonseca M, Hung LH, Kahn AL, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368:416-24; PMID:23363495; http://dx.doi.org/10.1056/NEJMoa1202541
   PubMed Web of Science ®Google Scholar
• Avdicova M, Crasta PD, Hardt K, Kovac M. Lasting immune memory against hepatitis B following challenge 10–11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11–12 months of age. Vaccine 2015; 33:2727-33; PMID:24962750; http://dx.doi.org/10.1016/j.vaccine.2014.06.070
   PubMed Web of Science ®Google Scholar
• Li R, Li CG, Li Y, Liu Y, Zhao H, Chen X, Kuriyakose S, Van Der Meeren O, Hardt K, Hezareh M, et al. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China. Vaccine 2016; 34:1436-43; PMID:26873055; http://dx.doi.org/10.1016/j.vaccine.2016.02.010
   PubMed Web of Science ®Google Scholar
• Wyman O. Global post-eradication IPV supply and demand assessment: integrated findings. Commissioned by the Bill & Melinda Gates Foundation and prepared by Oliver Wyman, Inc. March 2009. Available at: www.oliverwyman.com. Accessed 20 April 2011.
   Google Scholar
• Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007; 25:7041-6; PMID:17825459; http://dx.doi.org/10.1016/j.vaccine.2007.07.060
   PubMed Web of Science ®Google Scholar
• World Health Organization. Manual for the virological investigation of polio. WHO/EPI/GEN/97.01.44–51. 1997. Available at: http://www.who.int/mediacentre/factsheets/fs114/en/. Accessed 24 November 2011.
   Google Scholar
• World Health Organization. Expanded Programme on Immunization. Report of a WHO informal consultation on polio neutralizing antibody assays, Nashville, 5–6 December 1991. Geneva: (WHO/EPI/RD/913 Rev 1) 1991.
   Google Scholar